Connect
MJA
MJA

Glycaemic control in patients with type 1 diabetes after provision of public hospital-funded insulin pumps

Ken Y Thong, P Gerry Fegan and Bu B Yeap
Med J Aust 2009; 191 (5): 291.
Published online: 7 September 2009

To the Editor: In Australia, patients with type 1 diabetes and private health insurance are eligible for rebates on the purchase price of insulin pumps if deemed necessary for treatment. In contrast, hospital-funded or donated pumps are often used by non-insured patients. Hospitals may provide pumps to certain patients for various reasons — for example, to pregnant women (to improve their glycaemic control), to patients who want to try the pump to determine their preference or their ability to use it, or to patients waiting for private health insurance cover to be activated. Patient selection is important, as insulin pumps are cost-effective only if they reduce levels of glycated haemoglobin (HbA1c) and the frequency of hypoglycaemia1 — although quality of life may also be an important benefit.

  • Ken Y Thong1
  • P Gerry Fegan2
  • Bu B Yeap1,3

  • 1 Department of Endocrinology and Diabetes, Fremantle Hospital, Fremantle, WA.
  • 2 Department of Medicine, Fremantle Hospital, Fremantle, WA.
  • 3 School of Medicine and Pharmacology, University of Western Australia, Fremantle, WA.

Correspondence: kythong@gmail.com

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.